Beta Drugs share price
Last close ₹1,894.60down ₹76.40 (3.88%)
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,971.00.
52-week range of traded prices to 23 Oct 2026
₹990.10Low, 25 Feb 2026₹2,807.90High, 12 Aug 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹2,107 Cr1,305th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 22 Oct 2026
- 39.0
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 22 Oct 2026
- 4.8
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 22 Oct 2026
- 16.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 22 Oct 2026
- 14.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. The filing of 22 Oct 2026
- 0.10
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,55,58635.7% delivered
Results
Standalone, as consolidated accounts are on record for only 7 of the last ten years; ₹ crore, the charts by years to March, the table by quarter. No standalone results on record for the year to Mar 2023.Quarterly results
Quarter to Sep 2026, against the quarter beforeFiled 22 Oct
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹58 Crup 3.91%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹3.71 Crdown 37.44%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 6.4%
Revenue by year
Peak revenue ₹225 Cr, year to Mar 2026
Net profit by year, a loss in red
| ₹ crore | Dec 2025Filed 14 Feb | Mar 2026Filed 14 May | Jun 2026Filed 20 Jul | Sep 2026Filed 22 Oct |
|---|---|---|---|---|
| Revenue | 50.3 | 54.3 | 55.8 | 58.0 |
| Net profit | 3.3 | 5.3 | 5.9 | 3.7 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 6.5% | 9.8% | 10.6% | 6.4% |
Standalone. The 4 quarters from Dec 2025, the first on record; the half years before them are below. The latest is shaded.
| ₹ crore | Mar 2025Filed 15 May | Sep 2025Filed 6 Nov |
|---|---|---|
| Revenue | 102 | 121 |
| Net profit | 2 | 6 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 2.1% | 4.8% |
Standalone. The half years in the same span that the quarters on record do not fully cover.
Business segments
In the year to Mar 2026 the company reports one business segment, PHARMACEUTICAL, which carries all its revenue.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −37.6% | −7.5% | −32.5% | 0.0% |
| 3 years | +23.8% | – | – | 0.0% |
| 5 years | +58.2% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Beta Drugs in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Shukra PharmaceuticalsSHUKRAPHAR | 2,834 | 78.6 | 31.5 | 58.3 | +115.0% | +256.2% | 47.2% | 47.3% | 0.02% |
 HikalHIKAL | 2,388 | – | 2.0 | 13.2 | −5.4% | −153.4% | −2.7% | 3.5% | 0.31% |
 Fredun PharmaceuticalsFREDUN | 2,313 | – | 8.3 | 23.6 | – | – | – | 18.8% | 0.02% |
 Dishman Carbogen AmcisDCAL | 2,137 | 132.2 | 0.3 | 8.1 | +0.2% | −84.5% | 0.3% | 1.4% | 0.00% |
 Indoco RemediesINDOCO | 2,091 | 371.3 | 2.2 | 18.7 | +12.1% | – | 0.6% | 1.7% | 0.09% |
 Sai ParenteralsSAIPARENT | 2,040 | – | 4.2 | – | – | – | – | – | 0.00% |
 Syncom Formulations (India)SYNCOMF | 1,992 | 23.3 | 4.8 | 22.6 | +0.4% | +48.6% | 22.6% | 19.5% | 0.47% |
 Sakar HealthcareSAKAR | 1,980 | 46.2 | 5.7 | 22.4 | +48.0% | +119.8% | 13.2% | 16.6% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
16 Oct · Analysts
Sep 2026
Beta Drugs share price by year
Each calendar year to 2025.Beta Drugs share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,549.10 | −22.9% | 2,076.35 | 1,512.80 |
| 2024 | 2,009.00 | +36.7% | 2,251.75 | 1,083.00 |
| 2023 | 1,470.00 | +107.0% | 1,507.35 | 610.00 |
| 2022 | 710.00 | +10.9% | 956.45 | 515.00 |
| 2021 | 640.25 | +437.8% | 640.25 | 112.00 |
| 2020 | 119.05 | +56.9% | 135.30 | 39.00 |
| 2019 | 75.90 | −0.8% | 118.85 | 61.10 |
| 2018 | 76.50 | −59.1% | 202.25 | 58.10 |
| 2017 | 187.25 | – | 198.00 | 93.00 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2017 is from its first session, 12 Oct 2017.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 1,973.00 | 1,973.00 | 1,823.00 | 1,894.60 | 1,881.54 | 1,55,586 | 35.7% |
| 22 Oct 2026 | 1,664.70 | 1,997.60 | 1,616.00 | 1,971.00 | 1,878.69 | 5,67,442 | 15.8% |
| 21 Oct 2026 | 1,701.10 | 1,710.00 | 1,629.00 | 1,664.70 | 1,662.53 | 24,978 | 46.5% |
| 19 Oct 2026 | 1,779.80 | 1,779.80 | 1,700.00 | 1,719.60 | 1,736.77 | 18,555 | 46.9% |
| 16 Oct 2026 | 1,786.00 | 1,804.90 | 1,713.50 | 1,783.00 | 1,750.27 | 26,526 | 44.7% |
| 15 Oct 2026 | 1,700.00 | 1,870.00 | 1,674.20 | 1,750.30 | 1,809.59 | 1,61,207 | 28.1% |
| 14 Oct 2026 | 1,686.00 | 1,718.90 | 1,625.00 | 1,699.50 | 1,670.00 | 56,677 | 42.8% |
| 13 Oct 2026 | 1,845.00 | 1,859.40 | 1,660.00 | 1,677.70 | 1,712.68 | 1,25,336 | 54.8% |
| 12 Oct 2026 | 1,950.00 | 1,974.90 | 1,835.00 | 1,844.30 | 1,877.64 | 53,166 | 53.0% |
| 9 Oct 2026 | 1,910.00 | 1,974.00 | 1,703.10 | 1,950.20 | 1,814.58 | 1,58,957 | 38.3% |
Prices in ₹ per share as traded, not adjusted.
Company details
- Legal name
- Beta Drugs Limited
- NSE symbol
- BETA
- ISIN
- INE351Y01019
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Oct 2017
- Face value
- ₹10